Create Account | Sign In: Author or Forum

Search Symptoms

Category: Cardiology | Family Medicine | Geriatrics | Internal Medicine | Neurology | Nursing | Pharmacy | Institutional

Back to Journal Articles

Ranbaxy Issues Recall of 41 Batches of Atorvastatin

Last Updated: November 26, 2012.

Ranbaxy Laboratories Ltd., one of India's biggest pharmaceutical companies, has issued a voluntary recall for 41 batches of its generic version of atorvastatin calcium (Lipitor), according to the U.S. Food and Drug Administration.

MONDAY, Nov. 26 (HealthDay News) -- Ranbaxy Laboratories Ltd., one of India's biggest pharmaceutical companies, has issued a voluntary recall for 41 batches of its generic version of atorvastatin calcium (Lipitor), with the full knowledge of the U.S. Food and Drug Administration.

The voluntary recall, which includes 10-, 20-, and 40-mg doses of atorvastatin, was prompted out of concern that select batches may contain small glass particles, less than 1 mm in size. The recall affects lots packaged in 90 and 500 count bottles and only affects certain select lot numbers. The recall does not affect 80-mg doses of atorvastatin.

A complete list of the recalled lot numbers, bottle sizes, and dosages can be found on Ranbaxy's U.S. website.

"Ranbaxy is proactively recalling the drug product lots out of an abundance of caution, and in keeping the safety of our customers in mind," per a statement on Ranbaxy's U.S. website.

More Information
List of Affected Batches


Previous: More Novel Coronavirus Infection Cases Reported to WHO Next: Ob-Gyns Urged to Advocate Against Home Birth

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: